Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Press Releases
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société EISAI CO., LTD.
10/21BIOARCTIC : Interim Report for the period July - September 2021
AQ
10/17EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions ..
AQ
10/17EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions ..
PU
09/27EISAI : INITIATES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF ..
PU
09/27BIOARCTIC : Eisai initiates rolling submission for the US FDA Biologics license applicatio..
AQ
09/27EISAI : Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
AQ
09/27EISAI : Fully Human Anti-TNFα Monoclonal Antibody HUMIRA® Obtains Additional Approva..
PU
09/22EISAI : Italy awarded highest classification at sixth annual welfare index pmi* in italy
PU
09/21EISAI : Latest Value Creation Report (Former Integrated Report)
PU
09/15EISAI : To join the global emvironmental initiative 're100'
AQ
09/14EISAI : AbbVie, Eisai, and EA Pharma Launch 'Humira Support Tool Ordering Service for Pati..
AQ
09/14EISAI : to Join The Global Environmental Initiative "RE100"
AQ
09/14EISAI : TO JOIN THE GLOBAL EMVIRONMENTAL INITIATIVE “RE100”
PU
09/13EISAI : To present abstracts on oncology products and pipeline at esmo virtual congress 20..
PU
09/13EISAI : AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Pati..
AQ
09/13EISAI : AbbVie, Eisai, and EA Pharma Launch “Humira® Support Tool Ordering Service f..
PU
08/30EISAI : and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distrib..
PU
08/15EISAI : Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in ..
AQ
08/12MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combination for Fi..
AQ
08/11EISAI : FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Fi..
AQ
08/11EISAI : FDA Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Combination for ..
PU
08/05EISAI : Notification Regarding Revision of Consolidated Financial Forecasts for the Fiscal..
AQ
08/04EISAI : Receives award for excellence in corporate communications at the 37th corporate co..
PU
08/03EISAI : Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the..
PU
08/03EISAI : FY 2021 (Ending March 31, 2022) First Quarter Financial Results Reference Data
PU
08/03EISAI : CONSOLIDATED FINANCIAL REPORT for the Three-Month Period Ended June 30, 2021
PU
08/02BIOGEN : and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Obse..
AQ
08/02BIOGEN : Eisai Co., Ltd. - LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL CLINICAL EFF..
AQ
08/02EISAI : Anti-epileptic drug fycompa approved in china as monotherapy for partial-onset sei..
AQ
08/02EISAI : Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Sei..
AQ
08/01EISAI : Anti-epileptic drug fycompa® approved in china as monotherapy for partial-onset se..
PU
07/30EISAI : LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL CLINICAL EFFECTS OF LECANEMAB (..
PU
07/30BIOARCTIC : Eisai presented latest data from the lecanemab clinical program at AAIC 2021
AQ
07/29EISAI : and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BA..
AQ
07/29EISAI : Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-Worl..
AQ
07/29EISAI : Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially ..
AQ
07/27EISAI : Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at A..
PU
07/26EISAI : Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzhei..
AQ
07/23MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combination for Pa..
AQ
07/22EISAI : FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Pa..
AQ
07/21Eisai to present latest data on pipeline assets in the area of alzheimer's disease and ..
AQ
07/21EISAI : To present latest data on pipeline assets in the area of alzheimer's disease and d..
PU
07/20EISAI : to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and D..
AQ
07/19EISAI : Status of aduhelm in the united states
AQ
07/19EISAI : STATUS OF ADUHELM™ IN THE UNITED STATES
PU
07/19EISAI : Launches bile acid transporter inhibitor goofice® in thailand
PU
07/18EISAI : Launchs Bile Acid Transporter Inhibitor Goofice in Thailand
AQ
07/09BIOGEN : FDA Approves Updated ADUHELM Prescribing Information to Emphasize Population Stud..
AQ
07/09BIOARCTIC : Interim Report for the period April - June 2021
AQ
06/30EISAI : Launches in-house developed anti-insomnia drug dayvigo (lemborexant) in hong kong
AQ
06/30EISAI : Launches in-house developed anti-insomnia drug dayvigo® (lemborexant) in hong kong..
PU
06/29EISAI : Position and Policy Regarding Reduction in the Trading Unit of the Company's Share..
PU
06/24EISAI : Shelf registration for issuance of stock options
AQ
06/24EISAI : ANTICANCER AGENT 'TAZVERIK TABLETS 200mg' APPROVED IN JAPAN FOR EZH2 GENE MUTATION..
AQ
06/24BIOGEN : EISAI and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation f..
AQ
06/24BIOGEN : and Eisai Update for the Alzheimers Disease Community
AQ
06/24EISAI : and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecan..
AQ
06/23BIOARCTIC : FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer's disea..
AQ
06/23EISAI : Shelf registration for issuance of stock options
PU
06/23EISAI : Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In ..
AQ
06/21EISAI : Continuation of 'policy for protection of the company's corporate value and common..
AQ
06/18EISAI : Continuation of "policy for protection of the company's corporate value and common..
PU
06/18EISAI : Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-2..
AQ
06/16ER+/ HER2-VE BREAST CANCER PIPELINE : Emerging Therapies and Key pharma players involved b..
AQ
06/15ADVANZ PHARMA : enters into agreement to acquire the rights to Eisai's Zonegran in the EU ..
AQ
06/14EISAI : to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
AQ
06/14UNIVERSITY OF SOUTHERN CALIFORNIA : FDA's approval of aducanumab paves the way for 'more m..
AQ
06/09EISAI : Receives Special Prize at Platinum Career Award 2021
AQ
06/09EISAI : To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)
AQ
06/08MERCK : New data on keytruda (pembrolizumab) plus lenvima (lenvatinib) versus sunitinib in..
AQ
06/08EISAI : Japan may decide whether to approve new Alzheimer's drug by year-end
AQ
06/08EISAI : Biogen and Eisai launch initiatives to help patients with Alzheimer's disease acce..
AQ
06/08EISAI : FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's dise..
AQ
06/07EISAI : New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib
AQ
06/07UPDATE2 : U.S. approves new Alzheimer's drug developed by Biogen, Japan's Eisai
AQ
1  2  3  4  5  6Next
Upcoming event on EISAI CO., LTD.